FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.
What happened
FDA reviewed records the company submitted after FDA's March 11, 2024 and April 15, 2024 requests for records and other information under section 704(a)(4) of the FD&C Act. FDA found inadequate testing of incoming components, reliance on supplier test reports without establishing their reliability, an inadequate strength specification, and an ineffective quality unit. FDA placed the firm on Import Alert 66-40 on November 12, 2024.
What FDA found
The firm did not adequately test incoming components for identity and conformity with written purity, strength, and quality specifications, and it relied on supplier test reports (certificates of analysis) without establishing their reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not test each shipment of each lot of certain high-risk components for identity using United States Pharmacopeia (USP) tests that detect hazardous impurities, and it did not show a component meets its official USP specification.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not establish scientifically sound laboratory controls, including an adequate strength specification for the active ingredient through the product's shelf life.
21 CFR 211.160(b)The firm did not establish an adequate quality control unit with the responsibility and authority to approve or reject components and other materials.
21 CFR 211.22(a)
What FDA wants
FDA tells the firm to correct the violations promptly and to respond in writing within 15 working days with the corrective actions taken and steps to prevent recurrence. If corrections cannot be completed in that time, the firm must state the reasons for delay and provide a completion schedule.
Who should pay attention
- US importers and distributors of OTC drug products
- brands that use this contract manufacturer for finished drugs
- companies that rely on supplier certificates of analysis for high-risk drug components
This is a summary. Read the original letter on fda.gov.